Latest filing published 08 Oct 2025 for Verona Pharma plc.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Kathleen A. Rickard on record concern Verona Pharma plc, in the capacity of senior executive. In total, 55 filings cover trades dated from 1 August 2021 to 7 October 2025.
No open-market purchase appears, only 25 sales worth €5.2M. Outside the open market, there are 20 share grants and 7 option exercises. So far in 2025, the count stands at no purchases and 6 sales.
The record was last updated on 8 October 2025 with an option exercise in Verona Pharma plc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 31 declarations